InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled “Global Fragment-Based Drug Discovery Market by (technique (x-ray crystallography, nuclear magnetic resonance, surface plasmon resonance and other screening techniques), service (library screening, fragment screening and fragment optimization), End-users (hospitals, industry players and non-industry players) – Market Outlook and Industry Analysis 2030”

Get Demo Sample copy of Fragment-Based Drug Discovery Market Report at:

Over the last years, drug discovery programs have seen significant modifications, with the introduction of new technology continually altering the approach to drug discovery and design. Fragment-based drug discovery (FBDD) is a new strategy for decreasing attrition and finding leads for previously unsolvable biological targets that are becoming increasingly popular in the pharmaceutical business. The discovery of fragments that weakly bind the target protein, generally in the micromolar to millimolar affinity range, is the initial stage in the FBDD process. Fragments are organic molecules with a low molecular weight (less than 300 g/mol) that are extremely soluble. X-ray crystallography or NMR spectroscopy are utilized to identify the three-dimensional experimental binding mode of these fragments, which is employed to aid their optimization into potent compounds with drug-like characteristics.

In drug development and chemical biology, fragment-based techniques to identify new small compounds that bind to proteins are already well-established. This technique, which was mainly created in a few locations in the biotech and pharmaceutical industries, has now been extensively embraced in both the pharmaceutical business and academia. For the generation of early lead candidates, fragment-based drug discovery (FBDD) has become a well-established method. Despite its success and inherent benefits, however, FBDD’s hit-to-candidate progression may not always be faster than traditional high-throughput screening. As a result, new technology-driven library design methodologies have evolved as a way to make fragment screening and/or subsequent fragment-to-hit chemistry more efficient.

Market Dynamics:

The advancement of biophysical fragment screening technology has become one of the primary drivers of the global fragment-based drug discovery market. The demand for newer fragment-based drug development is growing as more complicated medical conditions emerge. Furthermore, the market for fragment-based drug discovery is dominating the biopharmaceutical businesses as a consequence of rising demand. In addition, one of the factors projected to fuel market expansion is an increase in the number of collaborations and partnerships, as well as significant funding and expenditures. For instance, in 2019, SpiroChem AG collaborated with Domainex Ltd on fragment discovery. Companies collaborated to provide hit expansion services for the resulting fragment hits, utilizing their respective chemistry teams’ combined knowledge. Domainex has added a broad range of SpiroChem fragments to its current fragment collection, which will be screened using the highly efficient and cost-effective FragmentBuilder platform.

North America dominated the market for Fragment-Based Drug Discovery. The significant share is attributable to the established healthcare infrastructure and high healthcare expenditure in the United States and Canada, which promotes access to innovative drug development.

For more Customization in this Report, Connect with us at:

The following key companies are engaged in the Fragment-Based Drug Discovery market:

2bind, Charles River Laboratories, ChemAxon, ComInnex, ChemDiv, Creative Biolabs, Creative Biostructure, CRELUX, Domainex, Evotec, Red Glead Discovery, SARomics Biostructures, Shanghai ChemPartner, Sygnature Discovery, Vernalis among others.

Get Extra Discount on Fragment-Based Drug Discovery Market Report, if your Company is Listed in Above Key Players List @

Tags: Fragment-based Drug Discovery Market